Geduld E E adds ACADIA Pharmaceuticals (ACAD) to its portfolio

ACADIA Pharmaceuticals (ACAD) : Geduld E E added new position in ACADIA Pharmaceuticals during the most recent quarter end. The investment management firm now holds 15,000 shares of ACADIA Pharmaceuticals which is valued at $478,050 , the company said in a statement filed on Aug 8, 2016 with the SEC.ACADIA Pharmaceuticals makes up approximately 0.66% of Geduld E E’s portfolio.

Other Hedge Funds, Including , Cable Hill Partners reduced its stake in ACAD by selling 5 shares or 3.36% in the most recent quarter. The Hedge Fund company now holds 144 shares of ACAD which is valued at $5,255.California Public Employees Retirement System reduced its stake in ACAD by selling 5,100 shares or 3.01% in the most recent quarter. The Hedge Fund company now holds 164,100 shares of ACAD which is valued at $6,099,597. ACADIA Pharmaceuticals makes up approx 0.01% of California Public Employees Retirement System’s portfolio.Swiss National Bank reduced its stake in ACAD by selling 5,300 shares or 3.39% in the most recent quarter. The Hedge Fund company now holds 151,004 shares of ACAD which is valued at $5,612,819. ACADIA Pharmaceuticals makes up approx 0.01% of Swiss National Bank’s portfolio.Huntington National Bank reduced its stake in ACAD by selling 49 shares or 64.47% in the most recent quarter. The Hedge Fund company now holds 27 shares of ACAD which is valued at $1,011.

ACADIA Pharmaceuticals opened for trading at $31.75 and hit $33.23 on the upside on Monday, eventually ending the session at $32.82, with a gain of 4.62% or 1.45 points. The heightened volatility saw the trading volume jump to 23,11,423 shares. Company has a market cap of $3,742 M.

On the company’s financial health, ACADIA Pharmaceuticals reported $-0.63 EPS for the quarter, missing the analyst consensus estimate by $ -0.16 based on the information available during the earnings call on Aug 4, 2016. Analyst had a consensus of $-0.47. The company had revenue of $.97 million for the quarter, compared to analysts expectations of $.71 million. The company’s revenue was up 96900.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.39 EPS.

Many Wall Street Analysts have commented on ACADIA Pharmaceuticals. ACADIA Pharmaceuticals was Downgraded by BofA/Merrill to ” Neutral” on Jun 22, 2016.

ACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for the treatment of neurological and related central nervous system disorders. The Company’s drug candidate NUPLAZID (pimavanserin) is under development for the treatment of Parkinson’s disease psychosis Alzheimer’s disease psychosis Schizophrenia and Sleep disturbances. The Company is also conducting preclinical programs for alpha adrenergic agonists indicated for the treatment of chronic pain and muscarinic drugs for the treatment of glaucoma. NUPLAZID has an active ingredient pimavanserin is a selective serotonin inverse agonist (SSIA) preferentially targeting 5-HT2A receptors that was discovered by the Company. The Company in collaboration with Allergan has discovered and engaged in the development of small-molecule product candidates such as alpha adrenergic agonists and muscarinic receptors.

Leave a Reply

ACADIA Pharmaceuticals - Is it time to Sell?

Top Brokerage Firms are advising their investors on ACADIA Pharmaceuticals. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.